Pirfenidone: Extent of added benefit assessed

January 3, 2012 in Diseases, Conditions, Syndromes

Pirfenidone inhibits the development of inflammation and scarring (fibrosis) in pulmonary tissue and has been approved for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) since the beginning of 2011. In an early benefit assessment in accordance with the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the extent of added benefit of pirfenidone.

Treatment with pirfenidone was compared with the appropriate comparator therapy, so-called best supportive care. This means the therapy that provides the patient with the best possible individually optimized supportive therapy to alleviate symptoms and improve quality of life (e.g. administration of additional drugs or ).

IQWiG found that there was an indication that pirfenidone gave minor added benefit with respect to patients' exercise tolerance. On the other hand, greater harm has been proven: Both study discontinuations and unfavourable effects on the were more frequent than with comparator therapy. The extent of this greater harm was classified as "minor" in each case. Harm to the skin was more frequent; IQWiG classified the extent of this as "considerable". The Institute weighed the benefits and harms and concluded that the extent of added benefit from pirfenidone should be classified as "no proven added benefit".

Manufacturers must submit dossiers for orphan drugs too

Pirfenidone (trade name Esbriet®) has been approved for the treatment of adults with mild to moderate idiopathic (IPF), a rare disease (orphan disease). In accordance with § 35a SGB V, an added benefit is regarded as proven if a drug for a rare disease, a so-called "orphan drug", has been approved. However, this does not mean that these drugs are not subjected to assessment. It is rather the case that they too require a dossier. This dossier must contain information about the patient groups for whom there is therapeutically important added benefit. Moreover, the manufacturer must describe the extent of the added benefit. The aim of the early benefit assessment is to establish the extent of the added benefit.

The legal ordinance on early benefit assessments specifies 6 categories for the extent of added benefit: If an added benefit is established, this may be "major", "considerable" or "minor", depending on the extent of improvement brought about by the drug. If there is added benefit, but this cannot be estimated based on the data available, this is regarded as "not quantifiable". The benefit of the drug to be assessed can also be "less than the benefit of the appropriate comparator therapy". If no added benefit can be established on the basis of the manufacturer's dossier, the ordinance specifies the category "no proven added benefit".

Studies provide data on patient-relevant outcomes

Two relevant studies with 435 (PIPF-004) and 344 (PIPF-006) patients were available for the dossier assessment. One group of study participants was treated with pirfenidone in combination with best supportive care and the comparator group was treated with best supportive care alone.

Both studies provided data for the patient-relevant outcome of mortality, as well as symptoms (morbidity) as measured by shortness of breath (dyspnoea), need for supplemental oxygen and exercise tolerance (6-min walk test). This also applies for the outcomes "health-related quality of life" and "side effects" ().

Minor added benefit and greater harm with non-serious outcomes

No added benefit could be proven for the outcomes "mortality", "health-related " and "morbidity", as measured by dyspnoea and supplemental oxygen treatment. The patients' exercise tolerance is an aspect of morbidity and was examined using the 6-min walk test. The proportion of the participants for whom the distance walked in 6 min decreased by more than 50 m in the course of the study was statistically significantly lower under pirfenidone treatment than under best supportive care alone. As however this criterion was only specified retrospectively (post hoc), IQWiG has demoted the certainty of the results from proof to indication.

The overall comparison of the adverse events and the serious adverse events found no difference between the treatment groups.

Thus greater harm under pirfenidone treatment could not be established for these outcomes.

However, there is proof for greater harm with respect to non-serious adverse events. The proportion of patients who discontinued treatment for this reason was greater under pirfenidone. Non-serious adverse events affecting the gastrointestinal tract or the skin were also observed more frequently.

Overall assessment balances the advantages and disadvantages

The overall conclusion on the extent of added benefit must consider both the indication of added benefit and the proof of greater harm. This consideration only applies to "non-serious" outcomes. The extent of the added benefit for exercise tolerance is classified by IQWiG as "minor". The Institute classifies the extent of harm (adverse events) as "minor" with respect to study discontinuations and the gastrointestinal tract and as "considerable" with respect to the skin.

As overall the submitted data provide no indication for added benefit from , the extent of the added benefit for this drug is then classified as "no proven added benefit" - as laid down in the legal ordinance.

The procedure for inferring the overall conclusion on the extent of the added benefit is a proposal from IQWiG. The G-BA will decide on the extent of the added benefit.

Provided by Institute for Quality and Efficiency in Health Care

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Flesh-Eating bacteria no cause for panic, experts say

(HealthDay) -- Despite scary headlines by the score, most people don't have to fear that they'll be the next victim of the so-called flesh-eating bacteria disease, experts say.

Diseases, Conditions, Syndromes created May 25, 2012 | popularity not rated yet | comments 0

World Health Assembly endorses new plan to increase global access to vaccines

Ministers of Health from 194 countries at the Sixty-fifth World Health Assembly today endorsed a landmark Global Vaccine Action Plan (GVAP), a roadmap to prevent millions of deaths by 2020 through more equitable access to ...

Diseases, Conditions, Syndromes created May 25, 2012 | popularity not rated yet | comments 0

Physicians definitively links irritable bowel syndrome and bacteria in gut

An overgrowth of bacteria in the gut has been definitively linked to Irritable Bowel Syndrome in the results of a new Cedars-Sinai study which used cultures from the small intestine. This is the first study to use this "gold ...

Diseases, Conditions, Syndromes created May 25, 2012 | popularity not rated yet | comments 0 | with audio podcast

Study provides compelling evidence for an effective new treatment for tinnitus

According to new research, a multidisciplinary approach to treating tinnitus that combines cognitive behaviour therapy with sound-based tinnitus retraining therapy is significantly more effective than currently available ...

Diseases, Conditions, Syndromes created May 24, 2012 | popularity not rated yet | comments 0

Infections may be deadly for many dialysis patients

An infection called peritonitis commonly arises in the weeks before many dialysis patients die, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings sugges ...

Diseases, Conditions, Syndromes created May 24, 2012 | popularity not rated yet | comments 0


Keep food safety in mind this memorial day weekend

(HealthDay) -- Picnics, parades and cookouts are as much a part of Memorial Day weekend as tributes to the United States' war veterans.

Travel to high altitudes tied to Crohn's, colitis flare-ups

(HealthDay) -- People with inflammatory bowel disease, which includes Crohn's disease and colitis, may be at increased risk for flare-ups when they fly or travel to high altitudes for skiing or mountain climbing, ...

Family history of Alzheimer's affects functional connectivity

(HealthDay) -- Cognitively normal individuals with a family history of late-onset Alzheimer's disease (AD) may display lower resting state functional connectivity in the default mode network (DMN) of the brain, ...

Transvaginal mesh op restores pelvic organ prolapse at price

(HealthDay) -- Transvaginal mesh (TVM) procedures are effective for anatomical restoration of pelvic organ prolapse (POP), but patients report a worsening of sexual function following surgery, according to ...

Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse

(Medical Xpress) -- Regardless of an organism’s biological complexity, every encephalized animal continuously makes under-informed behavioral choices that can have serious consequences. Despite its ubiquity, ...

Weight struggles? Blame new neurons in your hypothalamus

New nerve cells formed in a select part of the brain could hold considerable sway over how much you eat and consequently weigh, new animal research by Johns Hopkins scientists suggests in a study published in the May issue ...